Pipeline
First-in-Class Oral Therapeutics
EB613 for Osteoporosis
EB613 (Oral PTH(1-34),teriparatide) is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment of for post-menopausal women with low bone mineral density (“BMD”) and high-risk osteoporosis. EB613 is intended to provide an oral anabolic treatment earlier in an osteoporosis patient’s journey to increase skeletal mass, reduce the risk of fracture potentially limit the progression of the disease, and its associated disability and mortality.
EB612 for Hypoparathyroidism
The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement tablet therapy for hypoparathyroidism. We are currently testing new generations of our N-Tab™ Technology with the naked PTH(1-34) peptide to assess the effectiveness of once or twice a day dosing regimens, as well as collaborating with a third party on another peptide in this field.
Collaboration in SBS & Obesity
In September 2023, we entered into a research collaboration with OPKO Biologics, whereby OPKO supplies its proprietary long-acting GLP-2 peptide for short bowel syndrome (SBS) and certain Oxyntomodulin analogs for the development of oral tablet formulations for obesity, using our proprietary N-Tab™ technology.
